Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan

Andrew H KoDivision of Hematology/Oncology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA Abstract: Nanoliposomal irinotecan (nal-IRI) was originally developed using an efficient and high-loading capacity system to encapsulate irinot...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Ko AH
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	pancreatic cancer irinotecan nanoliposomal Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/61e14410da944e19b127ec1591f51a3c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:61e14410da944e19b127ec1591f51a3c
record_format	dspace
spelling	oai:doaj.org-article:61e14410da944e19b127ec1591f51a3c2021-12-02T01:32:09ZNanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan1178-2013https://doaj.org/article/61e14410da944e19b127ec1591f51a3c2016-03-01T00:00:00Zhttps://www.dovepress.com/nanomedicine-developments-in-the-treatment-of-metastatic-pancreatic-ca-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Andrew H KoDivision of Hematology/Oncology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA Abstract: Nanoliposomal irinotecan (nal-IRI) was originally developed using an efficient and high-loading capacity system to encapsulate irinotecan within a liposomal carrier, producing a therapeutic agent with improved biodistribution and pharmacokinetic characteristics compared to free drug. Specifically, administration of nal-IRI results in prolonged exposure of SN-38, the active metabolite of irinotecan, within tumors, while at the same time offering the advantage of less systemic toxicity than traditional irinotecan. These favorable properties of nal-IRI, confirmed in a variety of tumor xenograft models, led to its clinical evaluation in a number of disease indications for which camptothecins have proven activity, including in colorectal, gastric, and pancreatic cancers. The culmination of these clinical trials was the NAPOLI-1 (Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy) trial, an international Phase III study evaluating nal-IRI both alone and in combination with 5-fluorouracil and leucovorin in patients with metastatic pancreatic adenocarcinoma following progression on gemcitabine-based chemotherapy. Positive results from NAPOLI-1 led to approval of nal-IRI (with 5-fluorouracil/leucovorin) in October 2015 by the US Food and Drug Administration specifically for the treatment of metastatic pancreatic cancer in the second-line setting and beyond, a clinical context in which there had previously been no accepted standard of care. As such, nal-IRI represents an important landmark in cancer drug development, and potentially ushers in a new era where a greater number of patients with advanced pancreatic cancer can be sequenced through multiple lines of therapy translating into meaningful improvements in survival.Keywords: pancreatic cancer, irinotecan, nanoliposomal, clinical trial, NAPOLI-1Ko AHDove Medical Pressarticlepancreatic canceririnotecannanoliposomalMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2016, Iss default, Pp 1225-1235 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	pancreatic cancer irinotecan nanoliposomal Medicine (General) R5-920
spellingShingle	pancreatic cancer irinotecan nanoliposomal Medicine (General) R5-920 Ko AH Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan
description	Andrew H KoDivision of Hematology/Oncology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA Abstract: Nanoliposomal irinotecan (nal-IRI) was originally developed using an efficient and high-loading capacity system to encapsulate irinotecan within a liposomal carrier, producing a therapeutic agent with improved biodistribution and pharmacokinetic characteristics compared to free drug. Specifically, administration of nal-IRI results in prolonged exposure of SN-38, the active metabolite of irinotecan, within tumors, while at the same time offering the advantage of less systemic toxicity than traditional irinotecan. These favorable properties of nal-IRI, confirmed in a variety of tumor xenograft models, led to its clinical evaluation in a number of disease indications for which camptothecins have proven activity, including in colorectal, gastric, and pancreatic cancers. The culmination of these clinical trials was the NAPOLI-1 (Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy) trial, an international Phase III study evaluating nal-IRI both alone and in combination with 5-fluorouracil and leucovorin in patients with metastatic pancreatic adenocarcinoma following progression on gemcitabine-based chemotherapy. Positive results from NAPOLI-1 led to approval of nal-IRI (with 5-fluorouracil/leucovorin) in October 2015 by the US Food and Drug Administration specifically for the treatment of metastatic pancreatic cancer in the second-line setting and beyond, a clinical context in which there had previously been no accepted standard of care. As such, nal-IRI represents an important landmark in cancer drug development, and potentially ushers in a new era where a greater number of patients with advanced pancreatic cancer can be sequenced through multiple lines of therapy translating into meaningful improvements in survival.Keywords: pancreatic cancer, irinotecan, nanoliposomal, clinical trial, NAPOLI-1
format	article
author	Ko AH
author_facet	Ko AH
author_sort	Ko AH
title	Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan
title_short	Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan
title_full	Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan
title_fullStr	Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan
title_full_unstemmed	Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan
title_sort	nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/61e14410da944e19b127ec1591f51a3c
work_keys_str_mv	AT koah nanomedicinedevelopmentsinthetreatmentofmetastaticpancreaticcancerfocusonnanoliposomalirinotecan
_version_	1718403018663133184

Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan

Ejemplares similares